Q1 Earnings Forecast for TENX Issued By William Blair

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Stock analysts at William Blair issued their Q1 2026 earnings per share estimates for Tenax Therapeutics in a research note issued to investors on Wednesday, March 26th. William Blair analyst M. Phipps expects that the specialty pharmaceutical company will earn ($0.23) per share for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($0.88) per share. William Blair also issued estimates for Tenax Therapeutics’ Q2 2026 earnings at ($0.24) EPS, Q3 2026 earnings at ($0.23) EPS and Q4 2026 earnings at ($0.24) EPS.

Tenax Therapeutics (NASDAQ:TENX) last released its quarterly earnings data on Tuesday, March 25th. The specialty pharmaceutical company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.34.

A number of other research analysts also recently weighed in on TENX. StockNews.com assumed coverage on shares of Tenax Therapeutics in a research report on Saturday. They issued a “sell” rating for the company. Leerink Partners set a $20.00 price target on Tenax Therapeutics in a research note on Monday, March 10th. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Tenax Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $18.00.

Tenax Therapeutics Stock Performance

Shares of NASDAQ TENX opened at $6.49 on Thursday. The company has a market capitalization of $25.73 million, a PE ratio of -1.22 and a beta of 2.20. The company’s fifty day moving average price is $6.43 and its 200 day moving average price is $5.42. Tenax Therapeutics has a 1 year low of $2.77 and a 1 year high of $7.89.

Institutional Investors Weigh In On Tenax Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in TENX. Two Sigma Investments LP acquired a new stake in shares of Tenax Therapeutics in the fourth quarter valued at about $84,000. Sphera Funds Management LTD. purchased a new position in Tenax Therapeutics in the 3rd quarter valued at about $101,000. Geode Capital Management LLC boosted its holdings in Tenax Therapeutics by 32.4% in the 4th quarter. Geode Capital Management LLC now owns 24,354 shares of the specialty pharmaceutical company’s stock worth $151,000 after buying an additional 5,964 shares during the last quarter. Millennium Management LLC purchased a new stake in Tenax Therapeutics during the 4th quarter worth approximately $166,000. Finally, Stonepine Capital Management LLC purchased a new stake in Tenax Therapeutics during the 3rd quarter worth approximately $173,000. Hedge funds and other institutional investors own 1.67% of the company’s stock.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.